Integrum AB: Invitation to the Second Quarter 2023/24 Results Presentation

Report this content

Mölndal, Sweden – November 28, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its second quarter 2023/24 results on December 4, 2023 at 14:00 CEST.

Integrum’s CEO Rickard Brånemark will present the report together with CFO Jörgen Svanström and US President Jeffrey Zanni in a webcast. The presentation will be held in English.

Time: Monday, December 4, 2023 at 14:00 CEST.

Location: Webcast (see link below).

The report will be available at https://integrum.se/investor-relations/financial-reports-calendar/

The webcast and presentation material will be accessible via https://www.finwire.tv/webcast/integrum/q2-2023/  where it is also possible to ask questions.

For more information, please contact:

Rickard Brånemark, CEO

Phone: +46 (0) 70 846 10 61
E-mail: rickard.branemark@integrum.se

Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail:
Jorgen.svanstrom@integrum.se

Certified Adviser

Erik Penser Bank is Certified Adviser.

ABOUT INTEGRUM

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.